Earkart Limited
Earkart Manufacture and distribute modern hearing aids and related accessories at affordable price across India. Along with our own manufactured hearing aid, we also trade in hearing aid, parts and accessories of other brands manufactured in India and abroad.(Source : 202509 Prospectus Page No: 20)
- Market Cap ₹ 288 Cr.
- Current Price ₹ 209
- High / Low ₹ 266 / 136
- Stock P/E 53.1
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 45.1 %
- ROE 41.8 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 35.3%
Cons
- Company has high debtors of 159 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies
Part of BSE SME IPO
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 5.66 | 28.42 | 30.80 | 42.75 | |
| 5.52 | 26.79 | 27.22 | 32.96 | |
| Operating Profit | 0.14 | 1.63 | 3.58 | 9.79 |
| OPM % | 2.47% | 5.74% | 11.62% | 22.90% |
| 0.04 | 0.05 | 0.21 | 0.09 | |
| Interest | 0.01 | 0.08 | 0.36 | 0.44 |
| Depreciation | 0.06 | 0.15 | 0.19 | 0.42 |
| Profit before tax | 0.11 | 1.45 | 3.24 | 9.02 |
| Tax % | 0.00% | 9.66% | 5.86% | 23.61% |
| 0.11 | 1.31 | 3.06 | 6.88 | |
| EPS in Rs | 22.00 | 262.00 | 612.00 | 6.59 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 96% |
| TTM: | 39% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 297% |
| TTM: | 125% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 35% |
| Last Year: | 42% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 0.05 | 10.44 | 13.75 |
| Reserves | 4.72 | 6.49 | 12.97 | 9.48 | 52.31 |
| 0.27 | 1.23 | 4.02 | 4.96 | 5.62 | |
| 0.91 | 6.96 | 2.21 | 5.41 | 6.50 | |
| Total Liabilities | 5.95 | 14.73 | 19.25 | 30.29 | 78.18 |
| 0.22 | 0.25 | 1.06 | 1.17 | 1.61 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.46 | 0.10 | 0.19 | 0.83 | 0.83 |
| 4.27 | 14.38 | 18.00 | 28.29 | 75.74 | |
| Total Assets | 5.95 | 14.73 | 19.25 | 30.29 | 78.18 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -2.83 | -0.30 | -1.00 | 0.71 | |
| -1.78 | 0.40 | -1.29 | -1.32 | |
| 4.68 | 0.41 | 3.08 | -0.41 | |
| Net Cash Flow | 0.07 | 0.51 | 0.80 | -1.01 |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 104.47 | 60.36 | 75.13 | 158.55 |
| Inventory Days | 138.26 | 100.90 | 113.12 | 95.52 |
| Days Payable | 92.17 | 107.33 | 19.28 | 44.04 |
| Cash Conversion Cycle | 150.56 | 53.93 | 168.97 | 210.03 |
| Working Capital Days | 192.17 | 61.90 | 111.40 | 140.19 |
| ROCE % | 23.89% | 29.02% | 45.13% |
Documents
Announcements
-
Unaudited Standalone Financial Results Of The Company For The Quarter And Half Year Ended 30 September 2025 Along With Limited Review Report Issued By The Peer Reviewed Auditor M/S Gianender & Associates Chartered Accountants.
14 Nov - Board approved ESOP in-principle application; appointed secretarial auditor; approved Q2/H1 results for Sep 30, 2025.
-
Appointment Of N Kothari & Associates As Secretarial Auditor Of The Company For The FY 2025-26
14 Nov - 14 Nov 2025: Board approved unaudited Q2/half-year results (30 Sep 2025), appointed secretarial auditor, authorized ESOP application.
-
Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Earkart Limited Held On Friday, 14 November 2025.
14 Nov - Approved unaudited Q2/H1 results for 30 Sep 2025; in-principle ESOP authorization; appointed N Kothari & Associates.
-
Board Meeting Intimation for To Approve And Authorise For Having In-Principle Approval For Employee Stock Option Plan (Plan)
To Approve Incorporation Of Wholly-Owned Subsdiary Outside India
To Approve The Issuance Of Ncds.
3 Nov - Board meeting 14 Nov 2025: note listing; consider ESOPs, NCD issuance, overseas subsidiary incorporation.
-
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
29 Oct - Patent No. 572862 granted 29/10/2025 for Smart Sound Treatment and Diagnosis System.
Annual reports
No data available.
Business Profile[1]
Earkart manufactures and distributes modern hearing aids (BTE & RIC) and accessories, trades third-party hearing aids and parts, and also supplies mobility aids (foldable walkers) and educational/therapy kits (MSIED and TLM) for children with disabilities.